Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results
Authors
Keywords
Neuroendocrine tumours, Receptors, Progression-free survival, Somatostatin, Lanreotide
Journal
EUROPEAN JOURNAL OF CANCER
Volume 157, Issue -, Pages 403-414
Publisher
Elsevier BV
Online
2021-09-28
DOI
10.1016/j.ejca.2021.06.056
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Pavel et al. ANNALS OF ONCOLOGY
- Antiproliferative Effect Of Above-Label Doses Of Somatostatin Analogs For The Management Of Gastroenteropancreatic Neuroendocrine Tumors
- (2020) Leonidas Diamantopoulos et al. NEUROENDOCRINOLOGY
- Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor
- (2019) Giuseppe Lamberti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors
- (2018) Sally C. Lau et al. MEDICAL ONCOLOGY
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
- (2017) Jonathan Strosberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
- (2017) Stefano Severi et al. OncoTargets and Therapy
- Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
- (2016) James C Yao et al. LANCET
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
- (2014) Martyn E. Caplin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors
- (2012) Maxime Palazzo et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
- (2011) Marianne E Pavel et al. LANCET
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
- (2011) M. Herdman et al. QUALITY OF LIFE RESEARCH
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation